VERAMORPH LLC
Mansfield, MA · Founded 2022 · CIK 0001944210 · Biotech · Private
Software platform for optimizing drug formulation and delivery to maximize therapeutic efficacy
veramorph.com →- Grants
- $1.6M
- 3 awards
- Sector median: 1
- Raised
- $262K
- 2 Form D · Apr 2023
- 42 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Hydrogel tablets as cost-effective oral dosages for solubility enhancement | $225,000 | |
| Private capital raised | Form D · SEC | $222,250 | |
| Private capital raised | Form D · SEC | $40,000 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Design optimization and manufacturing scale-up of oral dosages with environmentally responsive polymers | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer | $399,985 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2608 | GABAeron, Inc. | — | — |
| 2609 | Curza Inc | — | $367K |
| 2610 | BreStem Therapeutics, Inc. | — | $300K |
| 2611 | VERAMORPH LLC | — | $262K |
| 2612 | XCELL SCIENCE, INC. | — | — |
| 2613 | AEROBYX, LLC | — | — |
| 2614 | TIBA BIOTECH, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul GodfrinDirector · Executive Officer
Patents
- Dissociating Polymer Matrix Compositions Of Fulvestrant And Methods Of Their Making And Useapplication
- Hydrogels As Oral Delivery Dosage Forms, Methods Of Making And Using Sameapplication
- Dissociating Polymer Matrix Compositions Of Fulvestrant And Methods Of Their Making And Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.